School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine ...

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports.

ARS Pharma reiterates its guidance that the company expects its cash, cash equivalents and short-term investments to be sufficient to fund its current operating plan for at least three years.

Preliminary neffy net product revenue for the fourth quarter of 2024 was approximately $6.5 million, with total net product ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 47.40% ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) shares gapped up before the market opened on Tuesday after Raymond James raised their price target on the stock from $26.00 to $28.00. The ...

The licensing deal includes substantial upfront and milestone payments. ARS Pharma is also exploring using its intranasal epinephrine technology for treating chronic urticaria, with a Phase 2b ...

neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). In November 2024, ARS Pharma announced ...

“For ARS Pharma, 2024 marked a pivotal year, securing regulatory approvals for neffy as the first and only intranasal epinephrine treatment, laying a solid foundation for our commercial success ...

and CEO of ARS Pharma. “neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis can ...

neffy was recently approved in the U.S. for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh ≥30 kg (66 lbs.). In November 2024, ARS Pharma ...

and CEO of ARS Pharma.“ neffy is a groundbreaking device with a simple, needle-free design that we believe will make schools safer and better prepared to address anaphylaxis. While anaphylaxis ...